This HTML5 document contains 126 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://dx.doi.org/10.12998/
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q64053512
rdf:type
wikibase:Item
schema:description
article scientifique publié en 2019 artículu científicu wetenschappelijk artikel наукова стаття, опублікована в березні 2019 im März 2019 veröffentlichter wissenschaftlicher Artikel
p:P577
wds:Q64053512-B9A9D03A-37AD-431D-A0EE-24522D435B80
wdt:P577
2019-03-26T00:00:00Z
p:P407
wds:Q64053512-B937F8C0-15B1-4E12-9EDB-8719AD7A7ED8
wdt:P407
wd:Q1860
p:P2860
wds:Q64053512-08D15FA4-615A-4C10-B0F8-4C8D400504BC wds:Q64053512-12954CCB-7411-4978-A262-10DBA29FF1BE wds:Q64053512-2A1DAAF2-06DD-4F5D-876B-88A18A28889D wds:Q64053512-23289E7E-8E80-48C6-9165-AA39BCCA9007 wds:Q64053512-6F6A9160-6BA1-4455-8EC4-81B44C271263 wds:Q64053512-71CD3086-F79E-4C50-9E4C-782843645E9A wds:Q64053512-7C73EBFC-23DC-4D9A-9471-6846805FAF10 wds:Q64053512-47AC753D-794C-4E57-9066-4378937847E9 wds:Q64053512-5145B7E6-78BC-4A80-824F-55F14A9F5627 wds:Q64053512-8BF5382D-2C58-4748-92A7-0E44E1FDC536 wds:Q64053512-7E0F3CB3-1415-4568-B4EA-198D91C7CB33 wds:Q64053512-84398496-04C2-4DB6-9683-7AFB3C15FCF2 wds:Q64053512-848FA95C-6A34-488A-A1E6-45F45E5EE9FC wds:Q64053512-994E6502-82C9-4A61-A6B0-2E911E3AE2AF wds:Q64053512-A1869DC8-1A88-4222-9C61-D7153C526F84 wds:Q64053512-CED4A264-BA0A-4CCD-8C66-03AAB51EFE27 wds:Q64053512-BCBA5999-565E-40A0-BFDE-DE2B2B554F68 wds:Q64053512-BF695899-0E9C-478B-99D4-2E43C28C5233 wds:Q64053512-DBD21C9A-A96C-4E8F-9659-32607708276B wds:Q64053512-E74D390E-98DE-4E69-9C99-CC08FD1842C2 wds:Q64053512-CFF20477-6D09-4A45-A195-D9FAA6690676 wds:Q64053512-D3BBBACE-C4DC-4993-BC3D-2CCD61311B9E
wdt:P2860
wd:Q55419778 wd:Q64255956 wd:Q30354326 wd:Q40431978 wd:Q81001377 wd:Q35762561 wd:Q45971394 wd:Q48351304 wd:Q34531692 wd:Q38044814 wd:Q44251901 wd:Q38178218 wd:Q30654037 wd:Q88645684 wd:Q30467845 wd:Q89209012 wd:Q38132994 wd:Q37998394 wd:Q38585467 wd:Q87392191 wd:Q30309827 wd:Q31041701
p:P2093
wds:Q64053512-E9400CD9-9597-48C8-8595-CD9AE61DA820 wds:Q64053512-95246DBB-D8BA-4878-AB8F-CC9E7147B0FF wds:Q64053512-B4ECC3DF-A758-4F42-A5DD-EF2696194F19 wds:Q64053512-CDC7AE59-761E-45AA-B5B4-C41E4D2C2784 wds:Q64053512-51CE46BC-2742-4A57-9917-79A2FF9FC4CE wds:Q64053512-67A7F6CD-EA2F-4C29-837B-6A6A3A0161B3 wds:Q64053512-85B93840-93B1-4C57-9F3E-24A433CDB9CA wds:Q64053512-8FD12302-1A88-4F1E-A48D-BC4C97D97680 wds:Q64053512-8745E7AC-03FB-4C3D-8C07-96505C16AB38 wds:Q64053512-05BC19BF-D8C9-4087-ACB4-3B8D9F463C58 wds:Q64053512-1BC818AF-0FE1-45E6-AD6C-33FBF7A39C73 wds:Q64053512-4438059E-E190-4662-BF53-33D3B4704AD9
wdt:P2093
Ken Kato Sho Watanabe Satoru Iwasa Fumihiko Matsumoto Hirokazu Shoji Kenya Kobayashi Atsuo Takashima Seiichi Yoshimoto Yoshitaka Honma Natsuko Okita Taisuke Mori Hidekazu Hirano
rdfs:label
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
skos:prefLabel
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
schema:name
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
p:P50
wds:Q64053512-ECEC1337-966A-498F-8F95-7F714EE1676E wds:Q64053512-C830E199-FBB3-4BDE-910F-CE81D26EFAED wds:Q64053512-B30D635E-811E-4A92-AD31-656B4CCC0FAE wds:Q64053512-B8239E85-E459-466B-80B5-3CAF56AF985E
wdt:P50
wd:Q88572199 wd:Q73264505 wd:Q60059555 wd:Q104585251
p:P1476
wds:Q64053512-1A1438CD-49A9-4AE0-93A7-8189700F785D
wdt:P1476
Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy for unresectable sinonasal undifferentiated carcinoma: Two cases of report
p:P304
wds:Q64053512-C24976A4-ACF8-4C45-BE0E-2719A3413255
wdt:P304
765-772
p:P31
wds:Q64053512-23841732-40be-4a46-85ae-c4edc1652155 wds:Q64053512-F5E941A7-EA35-4AD5-A1C6-F69DB99289B1
wdt:P31
wd:Q2782326 wd:Q13442814
p:P921
wds:Q64053512-E9C6DB14-62E7-4081-BEF7-79E5FFEE04C7 wds:Q64053512-E8AB21EE-F7D9-4A63-BFF9-3770303D6C4E wds:Q64053512-1CAD9690-7131-46AD-ABC6-60632E11C989 wds:Q64053512-30581755-C580-4E2C-BD30-CE4C95B20265 wds:Q64053512-9473F0A8-A873-4D5D-B45C-22F1BEFD7C8E wds:Q64053512-65607E7E-3594-4FD2-9882-019E44D9C5D8
wdt:P921
wd:Q420436 wd:Q2782326 wd:Q974135 wd:Q238512 wd:Q7524910 wd:Q5090613
p:P698
wds:Q64053512-BB74F7D0-FCFF-417E-868B-534A495CCA64
wdtn:P698
n11:30968042
wdt:P698
30968042
p:P1433
wds:Q64053512-D8DD7D11-4746-4F54-B6E3-E76DB7F4F1FB
wdt:P1433
wd:Q27725104
p:P433
wds:Q64053512-A930A084-DB69-4A4E-B700-BA84C2138D39
p:P478
wds:Q64053512-0E3DE9D5-4E5C-4452-A216-BA806EA77DBE
wdt:P433
6
wdt:P478
7
p:P356
wds:Q64053512-1CAFD051-4708-444D-9BDE-E145349174C3
wdtn:P356
n7:WJCC.V7.I6.765
wdt:P356
10.12998/WJCC.V7.I6.765
p:P932
wds:Q64053512-D745264A-48E8-4F9F-8323-3AD48A48BE3C
wdt:P932
6448077